What is ZBIO's health score?

Zenas BioPharma, Inc. (ZBIO) has a TradeApes health score of 44 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ZBIO's estimated fair value?

Based on our 5-year discounted cash flow model, Zenas BioPharma, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is ZBIO undervalued or overvalued?

Our model currently rates ZBIO as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for ZBIO... Refresh in a moment for the full analysis.

Zenas BioPharma, Inc. (ZBIO)

Healthcare Inconclusive inconclusive weak

$18.38

Updated: 2026-06-04

TradeApes Score

Financial Strength

45 Mixed

Operating Trend

40 Weak

Relative Value

40 Weak

Capital Allocation

30 Weak

Risk

80 Strong

Key Findings

+ Strong liquidity — current assets more than 2× current liabilities

Unlock Full Report →

− Excessive stock comp — SBC above 15% of revenue, wealth transfer to employees

Unlock Full Report →

Create an account for unlimited access

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.